At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Clonazepamdrug
Likely dose
Clonazepam intranasal, 1 doseAI-extracted
Key inclusion· 2
- ✓Diagnosis of refractory epilepsy
- ✓No nasal conditions that would preclude intranasal product use
Key exclusion· 2
- ✕Clinically significant unstable medical abnormality
- ✕Currently or regularly taking clonazepam
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Open-label,Proof -Of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
In Brief
A Phase 2 clinical trial evaluating Clonazepam for Epilepsy. Completed, enrolled 45 participants across 6 sites in 2 countries.
Detailed Summary
Evaluate the safety and efficacy of intranasal Clonazepam in subjects with epilepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesFinland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionDec 2008
Study CompletionJun 2009
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.5 years ago
Interventions
Clonazepamdrug
1 Dose